PORTFOLIO
Dreavent's portfolio showcases our investment in the most promising biotech companies poised to deliver tomorrow's cures, highlighting our dedication to groundbreaking healthcare advancements.
We focus on firms at the forefront of medical innovation, aiming to revolutionize treatment approaches and foster a healthier future.
Dreavent Engine 2026
The Dreavent Engine is a rigorous and structured process is designed to secure successful investments from the onset.
1.Ecosystem Crawling
The Dreavent Engine systematically and periodically scans the Biotech Ecosystem to identify potential investment targets.
2.Initial Filtering
The Engine performs an initial filter to select companies focusing on treatments for cancer, neurology, cardiovascular & metabolic disorders, and immunology.
3. Technology Assessment
A secondary filter is applied to narrow down the list to those companies utilizing established technologies.
4. Partner Evaluation
The refined list is then screened for companies with at least one large pharmaceutical investor with a successful investment history and one venture capitalist with a proven track record.
5. Expert Review
Dreavent’s team of experts and scientists review the filtered results, select a few candidates, and initiate the due diligence and decision-making process. Before finalizing a decision, the experts also conduct a Terms Review to ensure the investment conditions align with Dreavent's strategic objectives and risk management standards.
6. Investment and Monitoring
After selection, Dreavent commits to a holding period ranging from 3 to 7 years to ensure the investment reaches its potential.
The Dreavent Engine 2026 is gearing up for its 2024 investment cycle, with a strategy to allocate funds to five or six companies each year.
The initial funding target is set at $70 million, with an annual portfolio update aimed at reaching a cumulative investment of $210 million by 2026.
This deliberate approach maintains a steady stream of new investment possibilities, blending expert evaluation with methodical risk assessment to pinpoint promising ventures.
For a consultation with one of our specialists or to obtain more information, please complete the request form, and we will respond promptly.
Strategic Co-Investments with Industry Leaders
Dreavent collaborates with some of the largest pharmaceutical companies and financial venture capitalists in the industry. This co-investment strategy not only underscores our reliability but also demonstrates our strong connections within the sector. Partnering with these major players, we gain insights and access to high-quality investment opportunities, reflecting our solid standing in the biotech community.
Our ability to co-invest with leading pharmaceutical firms and financial VCs allows us to access exclusive deals typically reserved for the biggest names in the industry. This level of access is a testament to our well-established network and the trust we have earned. It positions us uniquely, ensuring we are at the forefront of innovative healthcare investments and contributing significantly to advancing the biotech landscape.
